Rx Industry Research Foundation Proposed By Sloan-Kettering Oncologist
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmaceutical companies should establish a collaborative foundation to explore common issues including pharmacogenomics and molecular oncology, Sloan-Kettering’s Norton says. Private sector cooperation is made easier by recent collaboration between government agencies, he maintains.
You may also be interested in...
CMS/NCI Collaboration Will Encompass Post-Approval Studies
Memorandum of understanding will create a mechanism to identify “high-priority clinical questions.” The collaboration also will examine off-label coverage of cancer drugs and reimbursement for new technologies.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said